Public limited company · Halen · incorporated on 15/05/1986 · 6,1 ETP
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 551,7 k € | +29.0% | 427,7 k € | +51.6% | 282,2 k € | -11.0% | 317,1 k € | -24.6% | 420,8 k € | +11.0% | 378,9 k € | +1.5% | 373,4 k € | +50.5% | 248,0 k € | +28.0% | 193,8 k € | -27.5% | 267,2 k € | -8.5% | 291,9 k € | +35.3% | 215,7 k € | +17.1% | 184,1 k € | +1.5% | 181,4 k € | -4.2% | 189,5 k € | -32.8% | 281,8 k € | +2.1% | 275,9 k € | +31.8% | 209,4 k € | +1.4% | 206,5 k € | |
| EBITDA | 180,6 k € | +126.0% | 79,9 k € | +82.6% | 43,8 k € | -0.9% | 44,2 k € | +255.2% | -28,4 k € | -142.3% | 67,2 k € | -34.2% | 102,1 k € | +126.2% | 45,1 k € | +2002.7% | -2,4 k € | -103.7% | 63,5 k € | -9.6% | 70,2 k € | +25.2% | 56,1 k € | +23.8% | 45,3 k € | -9.7% | 50,2 k € | -4.4% | 52,5 k € | -23.9% | 69,0 k € | +8.0% | 63,9 k € | -4.6% | 67,0 k € | -4.7% | 70,3 k € | |
| Operating profit | 80,6 k € | +387278.5% | -20,8 € | +99.9% | -19,8 k € | -39.7% | -14,2 k € | +78.1% | -64,8 k € | -283.7% | 35,3 k € | -46.7% | 66,2 k € | +3921.3% | 1,6 k € | +103.4% | -48,0 k € | -352.1% | 19,0 k € | -26.7% | 26,0 k € | +77.9% | 14,6 k € | +924.4% | 1,4 k € | -71.1% | 4,9 k € | +4231.6% | 114,0 € | -99.5% | 22,0 k € | +147.1% | 8,9 k € | -42.8% | 15,6 k € | -3.3% | 16,1 k € | |
| Profit/loss | 35,8 k € | +219.5% | 11,2 k € | +144.1% | -25,4 k € | -8054.0% | 319,8 € | +100.9% | -34,5 k € | -219.8% | 28,8 k € | -37.4% | 45,9 k € | +472.3% | -12,3 k € | +79.9% | -61,4 k € | -651.5% | 11,1 k € | -27.4% | 15,4 k € | +26.8% | 12,1 k € | +150.6% | 4,8 k € | -9.7% | 5,4 k € | +65.8% | 3,2 k € | -38.7% | 5,3 k € | +1672.7% | 297,0 € | +108.3% | -3,6 k € | -114.2% | 25,2 k € | |
| Equity | 118,7 k € | +43.2% | 82,9 k € | -62.7% | 222,1 k € | -10.3% | 247,5 k € | -16.0% | 294,8 k € | -10.5% | 329,3 k € | +9.6% | 300,5 k € | +18.0% | 254,6 k € | -4.6% | 266,9 k € | -18.7% | 328,4 k € | +3.5% | 317,2 k € | +5.1% | 301,9 k € | +4.1% | 290,0 k € | +1.5% | 285,6 k € | +1.8% | 280,6 k € | +1.0% | 277,8 k € | +1.8% | 273,0 k € | -0.0% | 273,1 k € | -1.4% | 277,1 k € | |
| Total assets | 1,3 M € | -6.4% | 1,3 M € | +9.6% | 1,2 M € | +7.6% | 1,1 M € | -8.1% | 1,2 M € | -2.3% | 1,3 M € | +24.7% | 1,0 M € | +0.3% | 1,0 M € | +5.3% | 958,0 k € | +0.8% | 950,5 k € | +21.8% | 780,6 k € | +12.2% | 695,8 k € | -7.3% | 750,8 k € | -4.8% | 788,9 k € | +16.9% | 674,7 k € | -3.2% | 696,7 k € | -3.0% | 718,5 k € | +4.3% | 688,9 k € | +3.1% | 668,3 k € | |
| Cash | 0,0 € | -100.0% | 245,7 € | +62.6% | 151,1 € | -99.1% | 16,7 k € | -91.3% | 192,7 k € | +2.6% | 187,8 k € | +1472.2% | 11,9 k € | -21.6% | 15,2 k € | +39127.8% | 38,9 € | -99.8% | 17,4 k € | -42.9% | 30,5 k € | +9589.5% | 315,0 € | +67.6% | 188,0 € | -97.5% | 7,6 k € | -27.0% | 10,5 k € | +98.3% | 5,3 k € | -42.5% | 9,2 k € | -61.5% | 23,9 k € | -41.3% | 40,7 k € | |
| Debts | 1,1 M € | -9.7% | 1,3 M € | +25.7% | 996,4 k € | +12.5% | 885,5 k € | -5.4% | 936,1 k € | +0.5% | 931,0 k € | +31.3% | 709,4 k € | -6.0% | 754,4 k € | +9.2% | 691,1 k € | +11.1% | 622,1 k € | +36.4% | 456,0 k € | +18.0% | 386,5 k € | -14.2% | 450,7 k € | -9.8% | 499,6 k € | +27.1% | 393,2 k € | -5.8% | 417,6 k € | -6.0% | 444,5 k € | +7.2% | 414,4 k € | +6.4% | 389,6 k € | |
| Staff | 6,1 | 5,7 | 4,6 | 5,4 | 5,5 | 6 | 6 | 4,9 | 3,7 | 4,9 | 5,5 | 3,7 | 2,1 | 3,7 | 3,7 | 5,6 | 5,2 | 3,6 | 3,5 | |||||||||||||||||||
Public limited company profitable and well capitalised. Cash position declining (-100.0%).
Acceptable counterparty for a moderate engagement. Require 2 fiscal years of detailed accounts before any significant exposure. The abridged model hides revenue.
NAQI is a Public limited company incorporated in 1986. Its main activity is: Manufacture of pharmaceutical preparations. Its registered office is in Halen. It employs on average 6,1 ETP workers (FTE).
Key indicators
7-day free trial, no credit card required.